Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) EVP Stephen P. Robertson Sells 19,402 Shares of Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) EVP Stephen P. Robertson sold 19,402 shares of the business’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $8.94, for a total value of $173,453.88. Following the completion of the sale, the executive vice president now owns 303,364 shares in the company, valued at $2,712,074.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH opened at $9.17 on Tuesday. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.07 and a 52-week high of $13.41. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -12.07 and a beta of 1.16. The business’s fifty day moving average is $7.98 and its 200 day moving average is $6.95.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last released its quarterly earnings data on Tuesday, February 28th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 25.44% and a negative net margin of 80.71%. The company had revenue of $28.40 million for the quarter, compared to analyst estimates of $28.82 million. During the same period in the previous year, the company posted ($0.25) EPS. The firm’s revenue for the quarter was up 21.4% compared to the same quarter last year. Equities analysts predict that Aurinia Pharmaceuticals Inc. will post -0.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Royal Bank of Canada restated an “outperform” rating and issued a $11.00 target price on shares of Aurinia Pharmaceuticals in a research note on Thursday, February 23rd. HC Wainwright lowered their target price on Aurinia Pharmaceuticals from $26.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, November 7th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.50.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC increased its stake in Aurinia Pharmaceuticals by 590.6% in the 4th quarter. Armistice Capital LLC now owns 5,000,000 shares of the biotechnology company’s stock worth $21,600,000 after acquiring an additional 4,276,000 shares during the last quarter. Bellevue Group AG increased its stake in Aurinia Pharmaceuticals by 6.6% in the 3rd quarter. Bellevue Group AG now owns 2,846,457 shares of the biotechnology company’s stock worth $21,405,000 after acquiring an additional 175,044 shares during the last quarter. State Street Corp increased its stake in Aurinia Pharmaceuticals by 2.2% in the 3rd quarter. State Street Corp now owns 2,441,434 shares of the biotechnology company’s stock worth $18,360,000 after acquiring an additional 53,572 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Aurinia Pharmaceuticals in the 4th quarter worth about $9,431,000. Finally, BlackRock Inc. increased its stake in Aurinia Pharmaceuticals by 0.4% in the 1st quarter. BlackRock Inc. now owns 1,827,416 shares of the biotechnology company’s stock worth $22,624,000 after acquiring an additional 6,677 shares during the last quarter. 40.36% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

(Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.